Ad26.ZEBOV Booster in Children Previously Vaccinated With Ad26.ZEBOV and MVA-BN-Filo (EBOVAC Booster Study)

Ebola Virus Disease Clinical Trial

Official title:

An Open Label Study to Evaluate the Safety and Immunogenicity of an Ad26.ZEBOV Booster Dose in Children Previously Vaccinated With the Ad26.ZEBOV and MVA-BN-Filo Vaccine Regimen

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04711356
• Other study ID #: VAC52150EBL2011
• Status: Completed
• Phase: Phase 2
• Start date: July 8, 2021
• Est. completion date: March 31, 2022

Study information

• Verified date: October 2021
• Source: London School of Hygiene and Tropical Medicine
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is an open-label study evaluating the safety and immunogenicity of a booster dose of Ad26.ZEBOV administered to children who were previously vaccinated with Ad26.ZEBOV followed by MVA-BN-Filo 56 days later.

Description:

RATIONALE: Over 600 children have received the adenovirus serotype 26 expressing the Ebola virus Mayinga glycoprotein (Ad26.ZEBOV), modified Vaccinia Ankara Bavarian Nordic vector expressing multiple filovirus proteins (MVA- BN-Filo) Ebola vaccine regimen in the EBL2002 and EBL3001 clinical trials. The vaccine regimen was well tolerated and highly immunogenic in children; however, the durability of vaccine-induced immune responses is not known. In adults previously vaccinated with the Ad26.ZEBOV and MVA-BN-Filo regimen, a booster vaccination with Ad26.ZEBOV was safe and induced a strong anamnestic response within seven days of the booster vaccination. It is important to establish if a booster dose of Ad26.ZEBOV is safe and immunogenic also in children, as this can guide the clinical use of the Ad26.ZEBOV, MVA-BN-Filo vaccine regimen in this age group. For example, it could support the strategy of boosting immunised children at the start of an Ebola outbreak. STUDY OBJECTIVES AND HYPOTHESIS: This study aims to evaluate the safety and immunogenicity of an Ad26.ZEBOV booster dose in healthy children who were previously (>2 years) vaccinated with the Ad26.ZEBOV (dose 1) followed by MVA-BN-Filo (dose 2) 56 days later, by monitoring adverse events (AEs) following the booster vaccination and by assessing binding antibody responses using the Filovirus Animal Non-Clinical Group (FANG) Enzyme-Linked Immunosorbent Assay (ELISA). Primary Objectives: - To assess the safety and tolerability of a booster dose of Ad26.ZEBOV at a dose of 5x10^10 viral particles (vp) in children previously vaccinated with the Ad26.ZEBOV, MVA-BN-Filo vaccine regimen with a 56-day interval. Safety and tolerability will be assessed by measuring: 1. Incidence of solicited local (at the administration site) and systemic adverse events as assessed on the day of booster vaccination and by diary card for 7 days after booster vaccination. 2. Incidence of unsolicited adverse events from the day of the booster vaccination to 28 days post booster vaccination. - To assess vaccine-induced humoral immune responses to the Ebola virus glycoprotein (EBOV GP), as measured by FANG ELISA (EU/ml), at 7 and 21 days following a booster dose of Ad26.ZEBOV at a dose of 5x10^10 vp in children previously vaccinated with the Ad26.ZEBOV, MVA-BN-Filo vaccine regimen with a 56-day interval. Exploratory Objectives • To assess neutralising antibody responses directed against the Ad26 vector before booster vaccination as measured by a virus neutralization assay (VNA). Hypothesis: as this study is designed to provide descriptive information regarding safety and immunogenicity without formal treatment comparisons, no formal statistical hypothesis testing is planned. OVERVIEW OF THE STUDY: This is an open-label study evaluating the immune response to a booster dose of Ad26.ZEBOV administered to children who were previously vaccinated with Ad26.ZEBOV followed by MVA-BN-Filo 56 days later. Only subjects who received the Ad26.ZEBOV and MVA-BN-Filo regimen during their participation in the VAC52150EBL3001 (EBOVAC-Salone) vaccine trial (ClinicalTrials.gov Identifier: NCT02509494), are eligible for enrolment in this study. Participants will be recruited in two age groups: children aged 4-11 years at the time of dose 1 vaccination and children aged 1-3 years at the time of dose 1 vaccination in the EBOVAC-Salone trial. Approximately 25 subjects will be enrolled in each of these two age groups. Parents/guardians will be asked to consent for the participation of their children in the study. Children aged 7 years and older at the time of enrolment in this study will be asked to give positive assent for their participation. Participants will be followed up to 28 days after their booster vaccination. The study will be conducted in Kambia, Sierra Leone. Study Population: potential participants must be healthy children (based on physical examination, medical history, a haematological assessment and clinical judgment) who received the Ad26.ZEBOV and MVA-BN-Filo vaccine regimen in the EBOVAC-Salone trial and were aged ≥1 to ≤11 years at the time of dose 1 vaccination. They must also be enrolled in the long-term follow-up study to the EBOVAC-Salone trial, VAC52150EBL3005 (EBOVAC-Salone Extension study, ClinicalTrials.gov Identifier: NCT03820739) but not in the immunogenicity subset. Dosage and administration: a single dose of Ad26.ZEBOV at a dose of 5x10^10 vp administered intramuscularly. Safety evaluations: solicited local (at the administration site) and systemic AEs will be assessed on the day of vaccination and using a diary for a period of 7 days following the booster vaccination. Unsolicited AEs will be tracked for 28 days following booster vaccination, while serious adverse events will be tracked for the duration of the study. Immunogenicity evaluations: blood will be drawn for assessments of immune responses at 7 and 21 days post booster vaccination. STATISTICAL METHODS: The primary analysis will be done when all subjects have completed their 28-day post-booster visit or discontinued earlier. This analysis will include all available data up to this point. Sample Size Determination: the sample size is a convenience sample and is not based on formal hypothesis testing considerations. Safety analysis: no formal statistical testing of safety data is planned. Safety data will be analysed descriptively by age group, 1-3 years and 4-11 years (age the participant was when they received dose 1 vaccination in the EBOVAC-Salone trial). Immunogenicity analysis: no formal hypothesis on immunogenicity will be tested. Descriptive statistics (i.e. geometric mean and 95% confidence interval, as appropriate) will be calculated for continuous immunologic parameters at all available time points. Graphical representations of immunologic parameters will be made as applicable. Frequency tabulations will be calculated for discrete (qualitative) immunologic parameters (i.e. responder rate), as applicable. Responders rate defined as >2.5-time increase over baseline value (or lower limit of quantitation [LLOQ]) pre-dose 1 vaccination in the EBOVAC-Salone trial, will be calculated depending on availability of sample results from the EBOVAC-Salone trial.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 50
• Est. completion date: March 31, 2022
• Est. primary completion date: September 17, 2021
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 3 Years to 16 Years

Eligibility

Inclusion Criteria:

1. Child must be enrolled in the VAC52150EBL3005 (EBOVAC-Salone Extension) study but not in the immunogenicity subset of EBOVAC-Salone Extension study.

2. Child must be a former participant in the VAC52150EBL3001 (EBOVAC-Salone) trial, and have received Ad26.ZEBOV (dose 1) vaccination followed by the MVA-BN-Filo (dose 2) vaccination within the EBOVAC- Salone trial window for dose 2 vaccination.

3. Child must have been aged 1 to 11 years old at the time of dose 1 vaccination in the EBOVAC-Salone trial.

4. The parent/guardian must consent for their child to participate in the VAC52150EBL2011 study. Children aged 7 years and older will be asked to give positive assent for their participation in the study.

5. The parent/guardian is willing/able to ensure that their child adheres to the prohibitions and restrictions specified in this protocol.

6. Child must be healthy in the investigator's clinical judgement (and the parent/guardian's judgement) on the basis of medical history, physical examination, vital signs, and a haematological assessment (i.e. full blood count) performed at screening. Subjects must meet the following haematology parameters within 28 days

before Day 1:

• Haemoglobin =8.0 g/dL for children aged 1 to <5 years, =9g/dL for children aged 5 or older
• Platelet count =100 x 10^9/L
• White blood cell count =5.0 x 10^9/L

7. Adolescent girls who have started their menstrual periods and/or are =12 years of age at the time of screening, must have a negative urine ß-hCG pregnancy test at screening and immediately prior to the booster vaccination on Day 1.

8. The parent/guardian is available and willing to have their infant participate for the duration of the study visits.

9. The parent/guardian must have a means to be contacted.

10. The parent/guardian must pass the Test of Understanding (TOU)

Exclusion Criteria:

1. Participants in the EBOVAC-Salone trial who were allocated to the control arm receiving the WHO- prequalified Meningococcal Group A, C, W135 and Y conjugate vaccine.

2. Participants in the EBOVAC-Salone trial who were age 12 years and older at the time of dose 1 vaccination.

3. Known allergy or history of anaphylaxis or other serious adverse reactions to vaccines or vaccine products (including any of the constituents of the study vaccine, e.g., polysorbate 80, ethylenediaminetetraacetic acid or L-histidine for Ad26.ZEBOV vaccine), including known allergy to chicken or egg proteins and aminoglycosides (gentamicin).

4. Presence of acute illness (this does not include minor illnesses such as mild diarrhoea or mild upper respiratory tract infection) or axillary temperature =38C on Day 1. Participants with such symptoms will be excluded from enrolment at that time but may be rescheduled for enrolment at a later date within the screening window.

5. Clinically significant history of skin disorder (e.g., psoriasis, contact dermatitis), allergy, symptomatic immunodeficiency, cardiovascular disease, respiratory disease, endocrine disorder, liver disease, renal disease, gastrointestinal disease, neurological illness as judged by the investigator or other delegated individual.

6. Adolescent girls who are known to be pregnant or breastfeeding at screening.

7. Received a blood transfusion or other blood products within 8 weeks of vaccination day.

8. Children who have been vaccinated with live-attenuated vaccines within 30 days before the study vaccination, and with inactivated vaccine within 15 days before the study vaccination.

9. Children who, in the opinion of the investigator, are unlikely to adhere to the requirements of the study or are unlikely to complete the vaccination and observation.

10. Any other finding which in the opinion of the investigator or other delegated individual would increase the risk of an adverse outcome from participation in the study.

Related Conditions & MeSH terms

• Ebola Virus Disease
• Hemorrhagic Fever, Ebola
• Virus Diseases

Intervention

Drug:
• Ad26.ZEBOV booster vaccination, given at a dose of 5x10^10 vp, via IM injection
Ad26.ZEBOV is a monovalent, replication-incompetent adenovirus serotype 26-based vector that expresses the full-length Ebola virus Mayinga glycoprotein

Locations

Country	Name	City	State
Sierra Leone	EBOVAC Kambia 1 clinic	Kambia

Sponsors (3)

Lead Sponsor	Collaborator
London School of Hygiene and Tropical Medicine	Innovative Medicines Initiative, University of Sierra Leone

Country where clinical trial is conducted

Sierra Leone, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Participants With Solicited Local (at the Administration Site) Adverse Events	Number and percentage of participants with at least one solicited local adverse event (i.e. pain, erythema, pruritus and swelling)	From the booster vaccination to 7 days post booster
Primary	Number of Participants With Solicited Systemic Adverse Events	Number and percentage of participants with at least one solicited systemic adverse event (i.e. arthralgia, chills, fatigue, headache, myalgia, nausea and pyrexia)	From the booster vaccination to 7 days post booster
Primary	Number of Participants With Unsolicited Adverse Events	Number and percentage of participants with at least one unsolicited adverse event	From the booster vaccination to 28 days post booster
Primary	Number of Participants With Serious Adverse Events	Number and percentage of participants with serious adverse events	From the booster vaccination to 28 days post booster
Primary	Pre-booster Baseline Humoral Immune Responses to the Ebola Virus Glycoprotein (EBOV GP)	EBOV GP antibody geometric mean concentration measured by FANG ELISA in Elisa Units (EU) per millilitre	day 1 before booster administration
Primary	Vaccine-induced Humoral Immune Responses to the Ebola Virus Glycoprotein (EBOV GP)	EBOV GP antibody geometric mean concentration measured by FANG ELISA in Elisa Units (EU) per millilitre	At 7 days post booster
Primary	Vaccine-induced Humoral Immune Responses to the Ebola Virus Glycoprotein (EBOV GP)	EBOV GP antibody geometric mean concentration measured by FANG ELISA in Elisa Units (EU) per millilitre	At 21 days post booster